Prophylaxis of cervical cancer and related cervical disease: A review of the cost-effectiveness of vaccination against oncogenic HPV types

Journal of Managed Care Pharmacy

Volumn 16, Issue 3, 2010, Pages 217-230

  Armstrong, Edward P ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE QUALITY; HIDDEN MARKOV MODEL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MATHEMATICAL MODEL; MEDICAL PRACTICE; QUALITY OF LIFE; REVIEW; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; VACCINATION; ADOLESCENT; ADULT; AGE; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH INSURANCE; IMMUNOLOGY; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; PHARMACOECONOMICS; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; UTERINE CERVIX TUMOR; VIROLOGY;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; MANAGED CARE PROGRAMS; MIDDLE AGED; MODELS, ECONOMIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; UTERINE CERVICAL DISEASES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77952355761     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.3.217     Document Type: Review

References (59)

1. Centers for Disease Control and Prevention (CDC). Impact of vaccines universally recommended for children - United States, 1990-1998. MMWR Morb Mortal Wkly Rep. 1999;48(12):243-48. Available at: http://www.cdc.gov/mmwr/ preview/mmwrhtml/00056803.htm. Accessed March 14, 2010.
2. Ehreth J. The global value of vaccination. Vaccine. 2003;21(7-8):596-600.
3. Centers for Disease Control and Prevention, Department of Health and Human Services. Report to Congress: prevention of genital human papillomavirus infection. January 2004. Available at: http://www.cdc.gov/std/HPV/ 2004HPV%20report.pdf. Accessed March 14, 2010.
4. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24(Suppl 3):S106-S13. (Pubitemid 44293025)
5. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-65. Available at: http://jcp.bmj.com/cgi/reprint/55/4/244. Accessed March 14, 2010. (Pubitemid 34293391)
6. Muñoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-27. Available at: http://content.nejm.org/cgi/ reprint/348/6/518.pdf. Accessed March 14, 2010.
7. Merck & Co. Highlights of prescribing information. Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, and 18] vaccine, recombinant] suspension for intramuscular injection Revised October 2009. Available at: http://www.merck.com/product/usa/pi-circulars/g/gardasil/gardasil-pi.pdf. Accessed March 14, 2010.
8. GlaxoSmithKline. Highlights of prescribing information. Cervarix (human papillomavirus bivalent [types 16 and 18] vaccine, recombinant]) suspension for intramuscular injection. Revised October 2009. Available at: http://us.gsk.com/products/assets/us-cervarix.pdf. Accessed March 14, 2010.
9. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621-32. Available at: http://www3.interscience.wiley.com/cgi-bin/fulltext/114205264/PDFSTART. Accessed March 14, 2010.
10. David MP, Van Herck K, Hardt K, et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the ASO4-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol. 2009;115(3 Suppl):S1-S6.
11. Centers for Disease Control and Prevention. HPV vaccine information for young women. June 26, 2008. Available at: http://www.cdc.gov/std/hpv/STDFact- HPV-vaccine-young-women.htm. Accessed March 14, 2010.
12. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. ACIP provisional recommendations for HPV vaccine. December 1, 2009. Available at: http://www.cdc.gov/vaccines/recs/provisional/ downloads/hpv-vac-dec2009-508.pdf. Accessed March 14, 2010.
13. National Committee for Quality Assurance. The state of health care quality 2008. Updated April 23, 2009. Available at: http://www.ncqa.org/Portals/ 0/Newsroom/SOHC/SOHC-08.pdf. Accessed March 14, 2010.
14. American Cancer Society. What are the key statistics about cervical cancer? Last revised January 19, 2010. Available at: http://www.cancer.org/ docroot/CRI/content/CRI-2-4-1X-What-are-the-key-statistics-for-cervical-cancer- 8.asp?sitearea=. Accessed March 14, 2010.
15. Wright TC, Jr. Cervical cancer screening in the 21st century: is it time to retire the PAP smear? Clin Obstet Gynecol. 2007;50(2):313-23. Available at: http://www.quimiolab.com/pdf/104-wright-07.pdf. Accessed March 14, 2010.
16. Myers E, Huh WK, Wright JD, Smith JS. The current and future role of screening in the era of HPV vaccination. Gynecol Oncol. 2008;109(Suppl 2):S31-S39. (Pubitemid 351658943)
17. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 2007;104(1):232-246 (Pubitemid 46054137)
18. American Cancer Society. American Cancer Society guidelines for the early detection of cancer. Last revised May 21, 2009. Available at: http://www.cancer.org/docroot/ped/content/ped-2-3x-acs-cancer-detection- guidelines-36.asp. Accessed March 14, 2010.
19. ACOG Committee on Practice Bulletins - Gynecology. ACOG Practice Bulletin No. 109: Cervical cytology screening. Obstet Gynecol. 2009;114(6):1409-1420
20. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813-19. Available at: http://jama.ama-assn.org/cgi/content/full/297/8/813. Accessed March 14, 2010. (Pubitemid 46333946)
21. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005;23(11):1107-1122
22. Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist. 2005;10(7):528-38. Available at: http://theoncologist.alphamedpress.org/cgi/reprint/10/7/528. Accessed March 14, 2010. (Pubitemid 41266334)
23. Eltoum IA, Roberson J. Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume: projections from the National Health Interview Survey (NHIS). Cancer. 2007;111(1):34-40. Available at: http://www3.interscience.wiley.com/cgi-bin/fulltext/114099805/ PDFSTART. Accessed March 14, 2010. (Pubitemid 46281082)
24. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol. 2004;191(1):114-120 (Pubitemid 39077963)
25. Max W, Rice DP, Sung H-Y, Michel M, Breuer W, Zhang X. The economic burden of gynecologic cancers in California, 1998. Gynecol Oncol. 2003;88(2):96-103.
26. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev. 2006;28:88-100.
27. Brisson, M, Edmunds, WJ. Economie evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making. 2003;23(1):76-82.
28. Elbasha EH, Dasbach EJ, Insinga RP, Haupt RM, Barr E. Age-based programs for vaccination against HPV. Value Health. 2009;12(5):697-707. [epub 2009 March 10]
29. Elbasha EH, Dasbach EJ, Insinga RP. A multi-type HPV transmission model. Bull Math Biol. 2008;70(8):2126-2176
30. Prasad SR, Hill R. Cost-benefit analysis on the HPV vaccine in Medicaid-enrolled females of the Appalachian region of Kentucky. J Ky Med Assoc. 2008;106(6):271-276
31. Chesson HW, Forhan SE, Gottlieb SL, Markowitz LE. The potential health and economic benfits of preventing recurrent respiratory pappillomatosis through quadrivalent human papillomavirus vaccination. Vaccine. 2008;25(35):4513-4518
32. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290(6):781-89. Available at: http://jama.ama-assn.org/cgi/reprint/290/6/781. Accessed March 14, 2010.
33. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96(8):604-15. Available at: http://jnci.oxfordjournals.org/cgi/reprint/96/ 8/604. Accessed March 14, 2010. (Pubitemid 38584984)
34. Rogoza RM, Ferko N, Bentley J, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine. 2008;26 (Suppl 5):F46-F58.
35. Centers for Disease Control and Prevention. Behavioral risk factor surveillance system. 2009. Available at: http://www.cdc.gov/brfss/. Accessed March 14, 2010.
36. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst. 2008;100(5):308-20. Available at: http://jnci.oxfordjournals.org/cgi/reprint/100/5/308. Accessed March 14, 2010.
37. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9(1):37-48. Available at: http://www.cdc.gov/ncidod/eid/vol9no1/02-0168.htm. Accessed March 14, 2010.
38. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10(11):1915-23. Available at: http://www.cdc.gov/ncidod/eid/vol10no11/04-0222.htm. Accessed March 14, 2008.
39. American Cancer Society. What are the key statistics about penile cancer? Last revised October 7, 2009. Available at: http://www.cancer.org/docroot/CRI/ content/CRI-2-4-1X-What-are-the-key-statistics-for-penile-cancer-35.asp?rnav= cri. Accessed March 14, 2010.
40. American Cancer Society. What are the key statistics about anal cancer? Last revised August 17, 2009. Available at: http://www.cancer.org/docroot/CRI/ content/CRI-2-4-1X-What-are-the-key-statistics-for-Anal-Cancer-47.asp?sitearea=. Accessed March 14, 2010.
41. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030-44. Available at: http://www3.interscience.wiley.com/cgi-bin/fulltext/112226580/PDFSTART. Accessed March 14, 2010.
42. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28-41. Available at: http://www.cdc.gov/ncidod/eid/13/1/pdfs/28.pdf. Accessed March 14, 2010.
43. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14(2):244-51. Available at: http://www.cdc.gov/eid/content/14/2/244.htm. Accessed March 14, 2010. (Pubitemid 351213674)
44. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359(8):821-32. Available at: http://content.nejm.org/cgi/reprint/359/8/821.pdf. Accessed March 14, 2010.
45. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009:339, b3884. Available at: http://www.bmj.com/cgi/reprint/339/oct08-2/b3884. Accessed March 14, 2010.
46. Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med. 2009;151(8):538-545
47. Haug C. The risks and benefits of HPV vaccination. JAMA. 2009;302(7):795-796
48. Viscidi RP, Schiffman M, Hildesheim A et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev. 2004;13(2):324-327
49. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423-28. Available at: http://content.nejm.org/cgi/reprint/338/7/423. pdf. Accessed March 14, 2010.
50. Trottier H, Mahmud S, Lindsay L et al. Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev. 2009;18(3):854-862
51. Dempsey AF, Cohn LM, Dalton VK, Ruffin MT. Human papillomavirus vaccine utilization: experiences of the first year. Presentation at: 43rd National Immunization Conference, March 2009; Dallas, TX. Abstract 53. Available at: http://cdc.confex.com/cdc/nic2009/webprogram/Paper17969.html. Accessed March 14, 2010.
52. Neubrand TP, Breitkopf CR, Rupp R, Breitkopf D, Rosenthal SL. Factors associated with completion of the human papillomavirus vaccine series. Clin Pediatr (Phila). 2009;48(9):966-969 [epub 2009 May 29]
53. Centers for Disease Control and Prevention(CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2008. MMWR Morb Mort Weekly Rep. 2009;58(36):997-1001. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a2.htm. Accessed March 14, 2010.
54. Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev Med. 2009;48(5):426-431
55. Neubrand TP, Breitkopf CR, Rupp R, Breitkopf D, Rosenthal SL. Factors associated with completion of the human papillomavirus vaccine series. Clin Pediatr (Phila). 2009;48(9):966-969
56. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302(7):750-57. Available at: http://jama.ama-assn.org/cgi/reprint/302/7/ 750. Accessed March 14, 2010.
57. Rascati KL. The $64,000 question - what is a quality-adjusted life-year worth? Clin Ther. 2006;28(7):1042-1043
58. Ronco G, Arbyn M, Segnan N. Cervical screening according to age and HPV status. BMJ. 2009;339:b3005.
59. Cannon HE. Pharmacy management of vaccines. J Manag Care Pharm. 2007;13(7 Suppl B):S7-S11. Available at: http://www.amcp.org/data/jmcp/pages%207-11.pdf.